Company Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD).
The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications.
Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test.
The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011.
Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
| Country | United States |
| Founded | 2009 |
| IPO Date | Jun 27, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 709 |
| CEO | Chad M. Robins M.B.A. |
Contact Details
Address: 1165 Eastlake Ave E Seattle, Washington 98109 United States | |
| Phone | 206-659-0067 |
| Website | adaptivebiotech.com |
Stock Details
| Ticker Symbol | ADPT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001478320 |
| CUSIP Number | 00650F109 |
| ISIN Number | US00650F1093 |
| Employer ID | 27-0907024 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Chad M. Robins M.B.A. | Co-Founder, Chief Executive Officer and Chairman |
| Julie Rubinstein | President and Chief Operating Officer |
| Dr. Harlan S. Robins Ph.D. | Co-Founder and Chief Scientific Officer |
| Kyle Piskel | Vice President, Chief Financial Officer and Principal Accounting Officer |
| Dr. Sharon Benzeno Ph.D. | Chief Commercial Officer of Immune Medicine |
| Christopher Carlson Ph.D. | Founder |
| Karina Calzadilla | Vice President of Investor Relations |
| Stacy L. Taylor | Senior Vice President, General Counsel and Corporate Secretary |
| Francis T. Lo | Chief People Officer |
| Susan Bobulsky | Chief Commercial Officer of MRD |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2024 | 8-K | Current Report |
| Apr 5, 2024 | 8-K | Current Report |
| Apr 2, 2024 | 8-K | Current Report |
| Feb 29, 2024 | 10-K | Annual Report |
| Feb 14, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 29, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 26, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 9, 2023 | 10-Q | Quarterly Report |